Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe to Cut Back on Jobs in Japan
November 4, 2015
- Mitsubishi Tanabe Sales Tick Up as Royalty Income Increases
November 4, 2015
- Daiichi Sankyo Recalls Measles, Rubella Vaccines
November 4, 2015
- Takeda Drops Development of TAK-264, TAK-272
November 2, 2015
- Sakigake Designation System Very Useful: Astellas President
November 2, 2015
- Eisai Squeezes Out Sales Rise on Growing Global Brands
November 2, 2015
- Daiichi Sankyo’s Half-Year Revenue Up 11% Due to Growth in Sales in Japan and US; Operating Profit Up 61%
November 2, 2015
- Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits
November 2, 2015
- Entyvio’s Sales Jump Underpins Takeda’s Half-Year Revenue
November 2, 2015
- Shionogi Delivers Record Profits in April-September on Brisk HIV Franchise
October 30, 2015
- Sakigake Designated Anticancer Agent ASP2215 Enters Multinational PIII Study: Astellas
October 30, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- DPT-IPV Vaccine Quattrovac to Be Out of Stock in November
October 29, 2015
- Yakult Licenses Novel Platelet Increasing Agent from Nissan Chemical
October 28, 2015
- Lupin Names Fabrice Egros As President of Asia Pacific, Japan Operations
October 28, 2015
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
- Lilly Joins NCC’s SCRUM-Japan Genomic Screening Project
October 26, 2015
- GSK to Transfer 3 Oncology Products to Novartis in Japan in November
October 26, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…